BIGGIOGGERO, MARTINA
BIGGIOGGERO, MARTINA
Dipartimento di Scienze Cliniche e di Comunità
A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: Focus on interchangeability
2017 A. Becciolini, M.G. Raimondo, C. Crotti, E. Agape, M. Biggioggero, E.G. Favalli
Alterations in the immune system of children from mothers treated with immunosuppressive agents during pregnancy
2004 R. Cimaz, E. Meregalli, M. Biggioggero, O. Borghi, A. Tincani, M. Motta, P. Airò, P. L. Meroni
Arthritis and infections
2005 R. Cimaz, E. Meregalli, M. Biggioggero, A. Casadei, P. Careddu
Baricitinib for COVID-19: a suitable treatment?
2020 E.G. Favalli, M. Biggioggero, G. Maioli, R. Caporali
Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic
2021 E.G. Favalli, G. Maioli, M. Biggioggero, R. Caporali
Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights
2021 M.G. Raimondo, M. Biggioggero, L.A. Coletto, A. Ramming, R. Caporali, E.G. Favalli
Comment on : Bisphosphonates and osteonecrosis of the jaw
2008 M. Bianchi, C. Limonta, J. Frasunkiewicz, M. Biggioggero, S. Vai
Cutting-Edge Issues in Coronary Disease and the Primary Antiphospholipid Syndrome
2013 R. Gualtierotti, M. Biggioggero, P. Meroni
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients : Results from the GISEA register
2014 M. Sebastiani, M.G. Anelli, F. Atzeni, C. Bazzani, I. Farina, A.L. Fedele, E.G. Favalli, I. Fineschi, N. Cino, I. Dal Forno, S. Gasparini, E. Cassarà, R. Giardina, E. Bruschi, O. Addimanda, G. Cassone, S. Lopriore, P. Sarzi-Puttini, M. Filippini, F. Pignatti, E. Gremese, M. Biggioggero, S. Manganelli, G. Amato, C. Caimmi, F. Salaffi, F. Iannone, C. Ferri, G. Sandri, G. Lapadula, R. Gorla, M. Govoni, G. Ferraccioli, A. Marchesoni, M. Galeazzi, R. Foti, A. Carletto, F. Cantini, G. Triolo, O.M. Epis, C. Salvarani
Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis : A multi-center retrospective analysis
2016 E.G. Favalli, C. Selmi, A. Becciolini, M. Biggioggero, A. Ariani, D. Santilli, E. Fusaro, S. Parisi, M. Massarotti, A. Marchesoni, P.L. Meroni
IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors
2007 R. Cimaz, M.A. Cazalis, C. Reynaud, V. Gerloni, F. Zulian, M. Biggioggero, G. Martini, I. Pontikaki, F. Fantini, B. Mougin, P. Miossec
Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants
2007 M. Biggioggero, M.O. Borghi, M. Gerosa, L. Trespidi, R. Cimaz, P.L. Meroni
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations
2022 A. Favalli, E.G. Favalli, A. Gobbini, E. Zagato, M. Bombaci, G. Maioli, E. Pesce, L. Donnici, P. Gruarin, M. Biggioggero, S. Curti, L. Manganaro, E. Marchisio, V. Bevilacqua, M. Martinovic, T. Fabbris, M.L. Sarnicola, M. Crosti, L. Marongiu, F. Granucci, S. Notarbartolo, A. Bandera, A. Gori, R. De Francesco, S. Abrignani, R. Caporali, R. Grifantini
Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis
2020 E.G. Favalli, S. Bugatti, C. Klersy, M. Biggioggero, S. Rossi, O. De Lucia, F. Bobbio-Pallavicini, A. Murgo, S. Balduzzi, R. Caporali, C. Montecucco
Is there a need for new thresholds to define remission and low disease activity by disease activity score 28 calculated with C reactive protein? real life data from a local registry
2015 E.G. Favalli, A. Becciolini, M. Biggioggero, A. Marchesoni, P.L. Meroni
Is there really room for anti-rheumatic drugs in the treatment of COVID-19?
2020 E.G. Favalli, F. Ingegnoli, M. Biggioggero, R. Caporali
Juvenile idiopathic arthritis in adulthood in a tertiary reference centre
2008 A. Salmaso, V. Gerloni, I. Pontikaki, B. Teruzzi, M. Biggioggero, M. Gattinara, F. Fantini
Methotrexate for the treatment of rheumatoid arthritis in the biologic era: Still an "anchor" drug?
2014 E.G. Favalli, M. Biggioggero, P.L. Meroni
Osteoporosis
2001 R. Cimaz, M. Biggioggero
Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors
2020 C. Bodio, C. Grossi, F. Pregnolato, E.G. Favalli, M. Biggioggero, A. Marchesoni, A. Murgo, M. Filippini, P. Migliorini, R. Caporali, R. Pellerito, F. Ciccia, P. Sarzi-Puttini, F. Perosa, G. Paolazzi, I. Hollan, K. Bendtzen, P.L. Meroni, M.O. Borghi